TheStreet upgraded shares of Innoviva (NASDAQ:INVA) from a c+ rating to a b rating in a research note published on Friday.

Several other brokerages have also recently issued reports on INVA. Stifel Nicolaus restated a hold rating and issued a $17.00 price target on shares of Innoviva in a research report on Friday. Zacks Investment Research cut shares of Innoviva from a hold rating to a sell rating in a research report on Saturday, February 3rd. BidaskClub upgraded shares of Innoviva from a hold rating to a buy rating in a research report on Thursday, December 21st. Robert W. Baird restated a hold rating and issued a $13.00 price target on shares of Innoviva in a research report on Tuesday, October 24th. Finally, Cowen set a $16.00 price target on shares of Innoviva and gave the company a buy rating in a research report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $13.83.

Innoviva (NASDAQ:INVA) opened at $15.45 on Friday. The stock has a market cap of $1,666.67, a P/E ratio of 13.92 and a beta of 2.52. Innoviva has a 12-month low of $11.02 and a 12-month high of $16.11. The company has a current ratio of 20.49, a quick ratio of 6.71 and a debt-to-equity ratio of -2.47.

Innoviva (NASDAQ:INVA) last released its quarterly earnings data on Thursday, February 8th. The biotechnology company reported $0.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. The business had revenue of $69.52 million during the quarter, compared to analysts’ expectations of $67.41 million. Innoviva had a net margin of 61.76% and a negative return on equity of 48.93%. The firm’s quarterly revenue was up 59.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.22 EPS. analysts anticipate that Innoviva will post 2.01 earnings per share for the current year.

In other news, VP George B. Abercrombie sold 5,215 shares of the company’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $13.26, for a total value of $69,150.90. Following the sale, the vice president now directly owns 263,866 shares of the company’s stock, valued at approximately $3,498,863.16. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Eric Desparbes sold 15,285 shares of the company’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $13.28, for a total transaction of $202,984.80. Following the completion of the sale, the chief financial officer now directly owns 337,027 shares in the company, valued at $4,475,718.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,522 shares of company stock valued at $429,985. Corporate insiders own 1.60% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Voya Investment Management LLC boosted its stake in shares of Innoviva by 10.1% in the 2nd quarter. Voya Investment Management LLC now owns 37,937 shares of the biotechnology company’s stock valued at $486,000 after purchasing an additional 3,470 shares during the last quarter. Cubist Systematic Strategies LLC boosted its stake in shares of Innoviva by 37.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 13,005 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 3,569 shares during the last quarter. Tealwood Asset Management Inc. boosted its stake in shares of Innoviva by 2.2% in the 4th quarter. Tealwood Asset Management Inc. now owns 194,633 shares of the biotechnology company’s stock valued at $2,762,000 after purchasing an additional 4,253 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Innoviva by 0.9% in the 4th quarter. Acadian Asset Management LLC now owns 502,352 shares of the biotechnology company’s stock valued at $7,129,000 after purchasing an additional 4,289 shares during the last quarter. Finally, LS Investment Advisors LLC boosted its stake in shares of Innoviva by 34.2% in the 3rd quarter. LS Investment Advisors LLC now owns 18,453 shares of the biotechnology company’s stock valued at $261,000 after purchasing an additional 4,707 shares during the last quarter. 74.22% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.watchlistnews.com/innoviva-inva-upgraded-to-b-at-thestreet/1863347.html.

About Innoviva

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Analyst Recommendations for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.